What Is Redemplo®? The World-First APOC3 siRNA Therapy for Precision Treatment of Familial Chylomicronemia Syndrome

What Is Redemplo? As the world-first APOC3 siRNA therapy, Redemplo® represents a significant advancement in RNA interference (RNAi)-based precision medicine for the treatment of Familial Chylomicronemia Syndrome (FCS).

In recent years, RNA interference (RNAi) technology has emerged as one of the most promising innovations in modern medicine, driving the development of precision therapies across a wide range of diseases. From rare genetic disorders to liver diseases and cardiometabolic conditions, RNAi therapies are transforming treatment strategies by targeting the underlying causes of disease rather than simply managing symptoms.

In July 2026, Redemplo® (Plozasiran Sodium Injection) became commercially available in China, marking an important milestone for patients with FCS. As the world’s first and currently the only approved APOC3-targeted small interfering RNA (siRNA) therapy, Redemplo® offers a novel mechanism-based treatment option designed to significantly reduce triglyceride levels in adults with this rare inherited lipid disorder.

For healthcare providers, pharmaceutical distributors, and qualified international buyers, the commercial availability of Redemplo® not only improves patient access to an innovative therapy but also creates new opportunities for global pharmaceutical sourcing and international procurement.

Key Product Information

Item	Details
Brand Name	Redemplo®
Generic Name	Plozasiran Sodium Injection
Drug Class	Small Interfering RNA (siRNA) Therapy
Target	Apolipoprotein C-III (APOC3)
Indication	Familial Chylomicronemia Syndrome (FCS) in Adults
Route of Administration	Subcutaneous Injection
Approved in China	January 2026
Commercial Launch in China	July 2026

What Is Redemplo® (Plozasiran Sodium Injection)?

What Is Redemplo® (Plozasiran Sodium Injection)? Redemplo® is the world’s first and currently the only approved APOC3-targeted small interfering RNA (siRNA) therapy, developed using advanced RNA interference (RNAi) technology. It is designed to address the underlying cause of Familial Chylomicronemia Syndrome (FCS) by targeting the genetic pathway responsible for severe hypertriglyceridemia.

Unlike conventional lipid-lowering medications, Redemplo® does more than simply reduce triglyceride levels. By specifically silencing the messenger RNA (mRNA) responsible for producing apolipoprotein C-III (APOC3), it targets the disease mechanism at its source. This precision approach helps improve triglyceride metabolism and provides a long-lasting treatment option for adults living with FCS.

In January 2026, Redemplo® (Plozasiran Sodium Injection) received approval from China’s National Medical Products Administration (NMPA) under the priority review pathway for use, in combination with dietary management, to reduce triglyceride levels in adults with Familial Chylomicronemia Syndrome. Following the completion of manufacturing, supply chain preparation, market access, and hospital distribution, the therapy was commercially launched in China in July 2026, making this innovative RNAi treatment available for clinical use.

As the world-first APOC3 siRNA therapy, Redemplo® represents a major milestone in precision medicine and expands the treatment options available for patients with this rare inherited lipid disorder.

What Is Familial Chylomicronemia Syndrome (FCS)?

Familial Chylomicronemia Syndrome (FCS) is an ultra-rare inherited lipid disorder caused by defects in the lipoprotein lipase (LPL) pathway, which prevents the body from properly breaking down triglyceride-rich chylomicrons. As a result, patients develop persistently and extremely high triglyceride levels, placing them at risk for serious and potentially life-threatening complications.

Because large amounts of chylomicrons accumulate in the bloodstream, the plasma of people with FCS often appears milky or creamy white. This characteristic appearance has led to the condition being informally referred to as “milky blood syndrome.” However, the appearance of the blood itself is not the primary concern.

The greatest health risk associated with FCS is the markedly increased risk of recurrent acute pancreatitis. Patients may experience repeated episodes of severe pancreatitis, which can lead to hospitalization, shock, multiple organ failure, and, in some cases, death. In addition to pancreatitis, persistently elevated triglyceride levels can significantly reduce quality of life and require lifelong disease management.

For many years, the cornerstone of FCS management has been strict dietary fat restriction, often requiring patients to follow a very low-fat diet while avoiding alcohol and other factors that may trigger pancreatitis. However, because FCS is caused by an inherited metabolic defect rather than lifestyle factors, conventional triglyceride-lowering medications frequently provide limited clinical benefit. As a result, there has long been an unmet need for targeted therapies that address the underlying disease mechanism, creating the opportunity for innovative treatments such as Redemplo® (Plozasiran Sodium Injection).

How Does Redemplo® (Plozasiran Sodium Injection) Work?

Plozasiran Sodium Injection is an APOC3-targeted small interfering RNA (siRNA) therapy that uses RNA interference (RNAi) technology to reduce the production of apolipoprotein C-III (APOC3) in liver cells.

APOC3 is a key regulator of triglyceride metabolism. Elevated APOC3 levels inhibit the activity of lipoprotein lipase (LPL) and impair the clearance of triglyceride-rich lipoproteins from the bloodstream. As a result, triglycerides accumulate in the blood, increasing the risk of severe complications such as acute pancreatitis, particularly in patients with Familial Chylomicronemia Syndrome (FCS).

By specifically targeting and degrading APOC3 messenger RNA (mRNA), Redemplo® reduces the production of the APOC3 protein at its source. This mechanism helps restore the body’s ability to metabolize triglyceride-rich lipoproteins more effectively.

As a result, Redemplo® may help:

• Reduce APOC3 protein production at the source
• Improve triglyceride metabolism
• Enhance the clearance of chylomicrons and other triglyceride-rich lipoproteins
• Significantly lower blood triglyceride levels
• Reduce the risk of serious complications, including recurrent acute pancreatitis

Unlike conventional lipid-lowering therapies that primarily manage blood lipid levels, Redemplo® targets the underlying molecular pathway responsible for FCS. This precision RNAi mechanism represents an important advancement in the treatment of rare lipid disorders and highlights the growing role of RNA interference technology in precision medicine.

Clinical Evidence: Results from the Phase 3 PALISADE Trial

The approval of Redemplo® (Plozasiran Sodium Injection) was primarily supported by data from the global Phase 3 PALISADE clinical trial, which evaluated its efficacy and safety in adults with Familial Chylomicronemia Syndrome.

The study demonstrated that patients treated with Redemplo® experienced a substantial reduction in fasting triglyceride (TG) levels as early as one month after treatment initiation. After 10 months of continuous treatment, the median fasting triglyceride level decreased by approximately 80% from baseline, highlighting the therapy’s durable triglyceride-lowering effect.

In addition to improving lipid control, treatment with Redemplo® was associated with an approximately 80% reduction in the risk of acute pancreatitis compared with placebo, representing a clinically meaningful benefit for patients with FCS, who are at high risk of recurrent pancreatitis.

Beyond meeting its primary efficacy endpoint, the PALISADE trial also achieved all key secondary endpoints while demonstrating a favorable safety profile. The overall incidence of adverse events was comparable to that observed in the placebo group, with no significant increase in kidney- or muscle-related adverse events, supporting the long-term use of this RNAi therapy.

Another important advantage of Redemplo®is its convenient dosing schedule. Administered as a subcutaneous injection once every three months, patients typically require only four doses per year. Compared with therapies that require more frequent administration, this extended dosing interval may help reduce the long-term treatment burden and improve patient adherence.

These findings demonstrate the potential of Redemplo®, the world’s first APOC3 siRNA therapy, to deliver sustained triglyceride reduction, lower the risk of acute pancreatitis, and provide an innovative precision treatment option for adults living with FCS.

Why Does the Commercial Launch of Redemplo® Matter?

Regulatory approval is a major milestone for any innovative medicine, but approval alone does not guarantee immediate patient access. Before a newly approved therapy can be used in routine clinical practice, manufacturers must complete a series of critical steps, including large-scale production, quality release, supply chain preparation, distribution, hospital access, and market implementation.

Redemplo® (Plozasiran Sodium Injection) received approval from China’s National Medical Products Administration (NMPA) in January 2026 under the priority review pathway. Following the completion of manufacturing, distribution, and market access preparations, the therapy was commercially launched in China in July 2026, making it available for clinical use.

For patients with Familial Chylomicronemia Syndrome (FCS), this commercial launch represents far more than a regulatory milestone. It marks the transition from clinical research to real-world patient access, allowing eligible patients to benefit from the world’s first APOC3 siRNA therapy through healthcare institutions.

The commercial availability of Redemplo® also reflects continued progress in improving access to innovative medicines for rare diseases in China. As more healthcare providers gain access to this precision therapy, eligible patients may benefit from earlier diagnosis, standardized disease management, and long-term treatment based on the underlying cause of FCS.

Redemplo® Procurement and International Supply Support

Following the commercial launch of Redemplo® (Plozasiran Sodium Injection) in China, interest in this innovative APOC3 siRNA therapy continues to grow among healthcare institutions, pharmaceutical distributors, and qualified buyers seeking access to advanced rare disease treatments.

As an international pharmaceutical supply platform specializing in innovative medicines, rare disease therapies, and specialty pharmaceuticals, DengYue Online Pharmacy closely follows the development of cutting-edge treatments worldwide. Through a compliant and efficient pharmaceutical supply chain, we provide professional sourcing support for healthcare partners and qualified international customers.

Our services may include:

• Innovative medicine sourcing consultation
• Pharmaceutical supply and distribution support
• International drug procurement assistance
• Export documentation and logistics consultation
• Cold chain transportation coordination
• Product availability verification and supply inquiries

DengYue Pharmacy works with qualified partners to facilitate access to innovative therapies while ensuring that all pharmaceutical supply activities comply with China’s export regulations and the applicable laws and requirements of destination countries or regions.

For healthcare institutions, distributors, and professional buyers interested in Redemplo® (Plozasiran Sodium Injection), our team can provide information regarding product availability, procurement procedures, and international supply support.

FAQ About The World-First APOC3 siRNA Therapy